Skip to main content
. 2017 Jun 21;7:4005. doi: 10.1038/s41598-017-04198-3

Figure 3.

Figure 3

Intrathecal injection of CaMKII specific-inhibitor AIP2 attenuates TCI-induced cancer pain and p-CREB up-regulation. Intrathecal injection of AIP2 significantly delayed or attenuated TCI-induced mechanical allodynia (A and C), thermal hyperalgesia (B and D), spontaneous flinches (E) and limb uselessness (F) in bone cancer rats. AIP2 (10 μM/10 μl, i.t.) or PBS (vehicle control, 10 μl, i.t.) was administered once daily on days 5, 6 and 7 (A and B) or days 12, 13 and 14 (C–F) after TCI. Behavioral tests were performed 4 hours after each injection. *P < 0.05, **P < 0.01 vs sham + PBS group; # P < 0.05, ## P < 0.01 vs TCI + PBS group; n = 8 for each group. (G and H) Inhibitory effect of AIP2 on p-CREB expression in TCI rats on day 7 or day 14. AIP2 (10 μM/10 μl, i.t.) or PBS (10 μl, i.t.) were administered once daily on days 5, 6 and 7 (G) or days 12, 13 and 14 (H) after TCI. L4-L6 spinal tissues were collected 4 hours after the last injection. **P < 0.01 vs sham + PBS group; # P < 0.05 vs TCI + PBS group; n = 4 for each group.